Pmel17/gp100
Rb, 1 ml RTU
Technische Daten
| Lagerung AK: | Store at 2 - 8 °C. Do not use after expiration date indicated on the vial. | | Kontrolle: | Melanoma | | Zelluläre Lokalisation: | Cytoplasmic | | Fixierung: | 1) NOTOXhisto 2) Formalin | | Anwendung AK: | IHC(p),IHC(f) | | Immunogen: | Synthetic peptide of human PMEL17 | | Ig Unterklasse: | IgG | | Spezies: | Rabbit | | Klon: | Polyclonal | | Format AK: | Ready-to-use | | Reaktivität AK: | Human, others not tested. | | Synonyme: | 95 kDa melanocyte specific secreted glycoprotein, D12S53E, gp100, M-beta, ME20, ME20 M/ME20 S, ME20-M, ME20-S, Melanocyte lineage specific antigen GP100, Melanocyte protein mel 17, Melanoma associated ME20 antigen, Melanoma gp100, Melanosomal matrix protein 17, Melanosomal matrix protein17, P1, p100, p26, PMEL 17, PMEL, Premelanosome protein, Secreted melanoma-associated ME20 antigen, SI, SIL, SILV, Silver (mouse homolog) like, Silver homolog, Silver locus protein homolog, Melanoma Associated Antigen, MAA | | Verfügbar in folgenden Ländern: | world wide (except US) | | Status: | IVD |
Beschreibung
Pmel17/gp100 is a type I transmembrane glycoprotein that is enriched in melanosomes (melanin-producing organelles in melanocytes) and plays a role in the biogenesis of melanosomes. Pmel17/gp100 is a melanoma-specific marker which is routinely used in the diagnosis of primary cutaneous malignant melanoma, clear cells sarcomas (melanoma of soft tissue), nevocellular nevi, and normal melanocytes.
Literatur
[1] Gown AM, Vogel AM, Hoak D et al. (1986):
Monoclonal antibodies specific for melanocytic tumors
distinguish subpopulations of melanocytes. Am J Pathol.
123:195-203.
[2] Ohsie SJ, Sarantopoulos GP, Cochran AJ and Binder
SW (2008): Immunohistochemical characteristics of
melanoma. J Cutan Pathol. 35(5):433-44.
[3] Wasmeier C, Hume AN, Bolasco G and Seabra MC
(2008): Melanosomes at a glance. J Cell Sci. 121(Pt
24):3995-9.
[4] Adema GJ, Bakker AB, de Boer AJ et al. (1996):
pMel17 is recognised by monoclonal antibodies NKIbeteb,
HMB-45 and HMB-50 and by anti-melanoma CTL.
Br J Cancer. 73(9):1044-8.
[5] Rothberg BE, Moeder CB, Kluger et al. (2008): Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions. H"Mod Pathol. 21(9): 1121-9.
|
